JMT108 for advanced melanoma and urinary tract cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug called JMT108 for advanced melanoma or urinary tract cancer. It may help your immune system attack the cancer, and the study is checking if it is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced melanoma or urinary tract cancer that cannot be removed with surgery or has spread.
- You have tried standard treatments or no standard treatment is available (for the early part of the study), or you may or may not have had standard treatment (for later parts).
- You are able to do light work and are not bedridden (ECOG score 0 or 1).
- You have not had certain prior treatments within the last 2–4 weeks, including chemotherapy, radiation, immunotherapy, or some targeted drugs.
- You have not had IL-2 or IL-15 therapy before, and you have no active or severe autoimmune disease or unstable brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests two experimental drugs, AK104 or AK112, combined with a targeted therapy called axitinib for people with metastatic mucosal melanoma (a rare type of skin cancer that has spread). The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial tests a new drug called JMKX005425 for people with advanced solid tumors that have a specific genetic feature called MSI-H or dMMR. If you have this feature and your cancer has not responded to other treatments, this study may offer a new option.
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
This trial tests a new drug called JMT108 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to see if the drug is safe and how it affects the body.
Hear when a new Unresectable Locally Advanced or Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.